Mar. 24, 2022
Reviva (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries. Visit RVPHinfo.com to learn more.
Bloomberg TV Show
CEO Interviews
"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."
1-800-REDCHIP (733-2447) | 431 E Horatio Ave, Suite #100, Maitland, FL 32751
"Discovering Tomorrow's Blue Chips Today." ® | Home | Contact | Privacy Policy | Disclosures
© 2024 RedChip Companies, Inc.